Record what happens when doctors use cancer drugs off-label
Cancer drugs are often prescribed outside their approved use based on hope or small studies. Capturing outcomes of these uses would reveal which ones fail so they can be stopped.
Off-label use is common in oncology, particularly for targeted agents matched to molecular alterations in other cancers. Structured outcome capture at the point of off-label prescribing (indication, rationale, response, duration, toxicity) through a simple registry, as the Dutch DRUP trial and the US TAPUR study do within trial frameworks, but extended to routine practice, would document failures that are otherwise invisible.
- Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
Pages like this
not linked directly; found by shared links- IdeaPre-registration and results reporting for real-world cancer studies
Shares Failures are hidden, Weak real-world evidence and registries, Real-world evidence.
- IdeaPay for new biomarker tests only while evidence of clinical utility is being collected
Shares Payers cover off-label combinations only inside registry-randomised trials, Real-world evidence.
- IdeaRegistry-embedded randomisation of treatment order in routine care
Shares Payers cover off-label combinations only inside registry-randomised trials, Weak real-world evidence and registries, Real-world evidence.
- IdeaA structured registry for every off-label cancer drug use
Shares Tumour-agnostic (tissue-agnostic) approval, Weak real-world evidence and registries, Real-world evidence.
- IdeaLinked prescribing and outcome data to find drug interactions with cancer therapy
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaWearable activity data as a validated real-world endpoint
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaNo mCODE, no payment: tie oncology reimbursement to a minimal structured record
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaGood practice standards and inspection for real-world data sources
Shares Weak real-world evidence and registries, Real-world evidence.